Back to discover
Drug

Acoramidis hydrochloride

Approved · EMA

Also known as Attruby, acoramidis (as hydrochloride), acoramidis HCl.

RxNorm2698313
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Beyonttra (EMA)

Regulatory2025-02-10EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Acoramidis hydrochloride
Aliases & brands
Attrubyacoramidis (as hydrochloride)acoramidis HCl
RxNorm CUI
2698313
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2025-02-10
Latest approval
2025-02-10
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2025-02-10Approval
Approval: Beyonttra (EMA)

Indication: For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.